Innovent Biologics, Inc. announced that the New Drug Application for IBI311, a recombinant anti-insulin-like growth factor 1 receptor antibody, has been accepted and granted priority review designation by the Center for Drug Evaluation of the China National Drug Administration for the treatment of Thyroid Eye Disease.
